Evercore ISI restated their in-line rating on shares of Bionomics (NASDAQ:BNOX – Get Rating) in a research note released on Tuesday, Benzinga reports. Evercore ISI currently has a $6.00 price target on the stock, down from their previous price target of $17.00.

Several other equities research analysts have also recently issued reports on BNOX. Loop Capital initiated coverage on Bionomics in a report on Tuesday, November 1st. They set a buy rating and a $23.00 price objective on the stock. HC Wainwright cut Bionomics from a buy rating to a neutral rating in a report on Monday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $16.67.

Bionomics Stock Performance

BNOX stock opened at $4.94 on Tuesday. Bionomics has a 52-week low of $4.94 and a 52-week high of $13.76. The stock's fifty day simple moving average is $7.62 and its 200-day simple moving average is $7.37.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

Further Reading

• Get a free copy of the StockNews.com research report on Bionomics (BNOX)
• Is There a Prize in Store for Kellogg Shareholders?
• Will AMC's Troubles Affect Its Landlord, EPR Properties?
• General Mills Retreats To More Attractive Territory
• Will Tesla Shares Rally If Musk Steps Down From Twitter?
• 5 Down But Not Out Stocks To Watch For 2023

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.